Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program

Physician Biography

Dr. Kluger is a medical oncologist who sees patients with melanoma, renal cell carcinoma and breast cancer. Her research interests focus on developing new drugs and biomarkers predictive of response to these drugs in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs and active research laboratory that studies tumors and cells from patients treated with novel therapies.

Clinical Interests

  • Breast Diseases
  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Melanoma Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology: Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (2002)

Clinical Trials

Conditions Study Title
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin Phase 1 Study of CM-24 in Subjects with Selected Advanced or Recurrent Malignancies
Soft Tissue Phase 1 study of safety & pharmacology with locally advanced or metastatic solid tumors
Melanoma, skin Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Melanoma, skin Stand Up To Cancer
Other Skin Merkel Cell Carcinoma (MCC) Therapy with MK-3475
Kidney A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monot
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Melanoma, skin Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Melanoma, skin Phase 1 Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
Melanoma, skin AdaptImmune Phase I/II Melanoma Trial
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Harriet Kluger, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520-8028